The Department of Health and Human Services (HHS) on Thursday released a comprehensive review of medical interventions for minors experiencing gender confusion, finding that risks for such treatments cannot be ignored and are not supported by science. The review identified a number of risks associated with intervention, including infertility, sexual dysfunction, and cardiovascular disease. “Despite increasing pressure to promote these drastic medical interventions for our nation’s youth, the review makes clear: the science and evidence do not support their use, and the risks cannot be ignored,” an HHS press release sent to The Daily Wire reads. “The ‘gender-affirming’ model of care includes irreversible endocrine and surgical interventions on minors with no physical pathology,” the review summary said. “These interventions carry risk of significant harms including infertility/sterility, sexual dysfunction, impaired bone density accrual, adverse cognitive impacts, cardiovascular disease and metabolic disorders, psychiatric disorders, surgical complications, and regret.” It also determined that there is “no independent association between gender dysphoria and suicidality,” and “no evidence that pediatric medical transition reduces the incidence of suicide, which remains, fortunately, very low.” The review found that the supposed benefits from medical intervention are severely in question and do not outweigh the risks. HHS also said that the perception of a “consensus” in support of these treatments is being pushed by medical associations, while dissent is stifled. “U.S. medical associations played a key role in creating a perception that there is professional consensus in support of pediatric medical transition,” the summary review said. “This apparent consensus, however, is driven primarily by a small number of specialized committees, influenced by WPATH (World Professional Association for Transgender Health). It is not clear that the official views of these associations are shared by the wider medical community, or even by most of their members. There is evidence that some medical and mental health associations have suppressed dissent and stifled debate about this issue among their members.” The evidence for benefits from pediatric medical intervention is “very uncertain,” the review stated, “while the evidence for harm is less uncertain.” Thus, the review suggested, medical professionals should not offer them, even if they are requested. “When medical interventions pose unnecessary, disproportionate risks of harm, healthcare providers should refuse to offer them even when they are preferred, requested, or demanded by patients,” it said. “Failure to do so increases the risk of iatrogenic harm and reduces medicine to consumerism, threatening the integrity of the profession and undermining trust in medical authority.” The review also recognized detransitioners, or individuals who received medical treatment for their gender confusion but later regretted such intervention. “The voices of whistleblowers and detransitioners have played a critical role in drawing public attention to the risks and harms associated with pediatric medical transition,” HHS said. “Their concerns have been discounted, dismissed, or ignored by prominent advocates and practitioners of pediatric medical transition.” Evaluating other forms of treatment for a gender-confused minor, HHS ridiculed the notion that psychotherapy could be deemed “conversion therapy.” “There is a dearth of research on psychotherapeutic approaches to managing gender dysphoria in children and adolescents,” the department said. “This is due in part to the mischaracterization of such approaches as ‘conversion therapy.’ A more robust evidence base supports psychotherapeutic approaches to managing common comorbid mental health conditions. Psychotherapy is a noninvasive alternative to endocrine and surgical interventions for the treatment of pediatric gender dysphoria. Systematic reviews of evidence have found no evidence of adverse effects of psychotherapy in this context.” The department underscored how minors and their families “require, and are entitled to, accurate, evidence-based information to guide their decisions,” and said this comprehensive review is for them, as well as policymakers, clinicians, therapists, and medical organizations.

German automaker Mercedes-Benz announced on Thursday that it will move production of one of its “core segment” vehicles to the United States, nearly a month after President Donald Trump’s 25% tariff on imported vehicles took effect. Mercedes did not specify which vehicle it will begin producing in the United States, but said that a “core vehicle segment” would be manufactured at a factory in Tuscaloosa, Alabama, Bloomberg reported. The automotive company plans to shift vehicle assembly to the United States by 2027. “We are getting even closer to the U.S. customer by localizing a core segment model in Tuscaloosa, strengthening our ties to the North American market where a range of Mercedes-Benz vehicles, including the GLE and GLS models, have their roots,” said Mercedes-Benz North America CEO Jason Hoff. The White House celebrated the announcement from Mercedes, saying in a statement, “Today, Mercedes-Benz announced it will move production of another vehicle to the U.S. — the latest result of President Donald J. Trump’s relentless pursuit of American manufacturing dominance.” Mercedes added that the Alabama plant has become “the global export hub for Mercedes-Benz SUVs.” The Mercedes GLC sport utility vehicle has become increasingly popular in the United States, seeing a 58% increase in sales last year. Bloomberg reported last month that Mercedes was considering pulling its least expensive vehicles from the U.S. market due to tariffs. Earlier this week, Trump struck a deal with the auto industry to provide some tariff relief in return for commitments to bring more manufacturing back to the United States. Under new tariff rules, auto manufacturers will continue to pay a 25% tariff on imported vehicles, but they will not be subject to any additional levies, such as those on steel and aluminum. American auto CEOs thanked Trump for the tariff relief and pledged to continue seeking ways to increase domestic production. Other foreign auto companies have also said they will ramp up investments in the United States following Trump’s tariffs. Hyundai announced a $21 billion investment in the United States over the next four years, starting with a steel plant in Louisiana that is expected to create nearly 1,500 jobs. BMW, another German automaker, is also looking to boost manufacturing in the United States.

Deputy Chief of Staff Stephen Miller went on an absolute tear during Thursday morning’s White House press briefing, reaffirming President Donald Trump’s commitment to ending “barbaric” child gender transitions — whether chemical or surgical — saying that they amounted to “child torture” and “medical malpractice.” Miller began with the executive orders issued by President Trump early on — ending policies supported by former President Joe Biden and the Democrats that had allowed men to play women’s sports and change in their private locker rooms — and then pivoted to more recent moves aimed at ending all gender transition procedures for minors. WATCH: .@StephenM: “It is CHILD ABUSE to change a child’s gender … Castration surgeries, castration drugs, sterilization treatments of children are barbaric. They violate all sound medical ethics. They are completely unwarranted. They harm children for life — irreversibly.” pic.twitter.com/AMNM6eXTau — Rapid Response 47 (@RapidResponse47) May 1, 2025 “This administration ended the Biden administration’s policy and the Democrat Party’s policy of allowing men into women’s sports, men into women’s spaces,” Miller began. “We are using every single legal and financial tool we have at President Trump’s direction to make it clear that schools and universities are and will lose federal funds, as you’ve seen in Maine, if you allow men to invade women’s sports and women’s spaces.” Miller went on to say that the administration’s policies applied to every school in the K-12 system, adding, “The Department of Justice is also coordinating with state and local law enforcement to fight child abuse in our school system. It is child abuse to change a child’s gender, particularly if you do not inform the parents. In other words, if a five-year-old or a six-year-old goes to school, or a seven-year-old goes to school, and the teacher tries to turn the boy into a girl and a girl into a boy, that is child abuse, and this administration is treating that as child abuse. And it is a gross violation of parental rights.” Miller then directed the message from the administration to hospital systems across the country, saying that they would not be able to funnel taxpayer dollars into gender transition programs. “Castration surgeries, castration drugs, sterilization treatments of children are barbaric. They violate all sound medical ethics. They are completely unwarranted. They harm children for life — irreversibly,” Miller said. “It is child torture. It is child abuse. It is medical malpractice.”

'I think you should f*ck off'

'Extraordinary extraterritorial reach'